All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

How do you use MRD to guide treatment decisions?

During the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting, the Lymphoma Hub was pleased to speak to Othman Al-Sawaf, University Hospital Cologne, Cologne, DE. We asked, How do you use minimal residual disease (MRD) to guide treatment decisions?

How do you use MRD to guide treatment decisions?

Al-Sawaf discusses MRD as a prognostic tool in the management of chronic lymphocytic leukemia. Al-Sawaf also mentions MRD assessments, clinical studies and continuous individualized risk index.

 

Share: